10:06 AM EST - Kinaxis : Announced that Swedish Orphan Biovitrum AB (Sobi), a leading international biopharmaceutical company, has elected to implement the Kinaxis Maestro® platform to facilitate end-to-end collaboration across its partner network, enable data-driven decisions and support the delivery of critical therapies to patients with rare diseases. Kinaxis
shares T.KXS are trading up $0.30 at $179.30.
